Open AccessEvidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
Author(s) -
Anker Stefan D.,
Coats Andrew J. S.,
Morley John E.
Publication year - 2015
Publication title -
journal of cachexia, sarcopenia and muscle
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.803
H-Index - 66
eISSN - 2190-6009
pISSN - 2190-5991
DOI - 10.1002/jcsm.12063
Subject(s) - anorexia , cachexia , ghrelin , appetite , medicine , skeletal muscle , food intake , muscle mass , cancer , endocrinology , cancer cachexia , hormone
A major component of the cancer anorexia‐cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin‐analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.